Trans Genic Inc. (JP:2342)
:2342
Want to see JP:2342 full AI Analyst Report?
Top Page
Trans Genic Inc.
(2342)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥209.00
▼(-17.72% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance—especially sustained negative free cash flow and inconsistent profitability—despite moderate leverage and some operating improvement in 2026. Technical indicators add downside pressure with the stock trading below key moving averages and a negative MACD. Valuation is also penalized by a negative P/E tied to ongoing losses.
Positive Factors
Balance sheet support
The company's moderate debt-to-equity (improving in 2026) and sizable equity base create a durable financial buffer. That balance-sheet strength reduces near-term refinancing pressure and supports ongoing R&D and service operations over the next several months, giving management time to stabilize profits.
Negative Factors
Persistent negative free cash flow
Sustained negative free cash flow across multiple years signals ongoing cash burn and weak internal funding. That pattern increases the likelihood the company will need external financing, which can dilute shareholders or raise interest costs, and limits organic reinvestment capacity over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet support
The company's moderate debt-to-equity (improving in 2026) and sizable equity base create a durable financial buffer. That balance-sheet strength reduces near-term refinancing pressure and supports ongoing R&D and service operations over the next several months, giving management time to stabilize profits.
Read all positive factors
Trans Genic Inc. (2342) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.61B
Dividend YieldN/A
Average Volume (3M)549.15K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth1.30%
EPS Growth92.91%
CountryJP
Employees236
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-57.85
Shares Outstanding16,999,142
10 Day Avg. Volume1,508,680
30 Day Avg. Volume549,150
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)0.89
Price to Sales (P/S)0.32
P/FCF Ratio-100.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Trans Genic Inc. Business Overview & Revenue Model
Company Description
Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and In...
How the Company Makes Money
null...
Trans Genic Inc. Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.32B | 13.17B | 13.01B | 13.08B | 11.43B | 12.58B |
| Gross Profit | 2.28B | 2.43B | 2.17B | 2.25B | 1.99B | 3.84B |
| EBITDA | 76.02M | 293.56M | -64.37M | 253.62M | 158.37M | 2.07B |
| Net Income | -963.26M | -77.27M | -1.09B | 4.08M | -409.67M | 1.88B |
Balance Sheet | ||||||
| Total Assets | 9.72B | 9.74B | 9.59B | 9.84B | 10.68B | 10.44B |
| Cash, Cash Equivalents and Short-Term Investments | 2.30B | 2.13B | 2.56B | 2.48B | 3.46B | 4.62B |
| Total Debt | 2.85B | 2.09B | 2.58B | 2.26B | 2.43B | 1.86B |
| Total Liabilities | 4.87B | 4.90B | 4.73B | 3.84B | 4.56B | 3.80B |
| Stockholders Equity | 4.79B | 4.78B | 4.76B | 5.89B | 6.02B | 6.53B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -42.55M | -81.35M | -658.12M | -1.74B | 1.26B |
| Operating Cash Flow | 0.00 | 25.91M | 94.10M | -392.45M | -1.43B | 1.79B |
| Investing Cash Flow | 0.00 | 50.87M | -287.85M | -280.93M | -216.02M | 981.87M |
| Financing Cash Flow | 0.00 | -518.46M | 265.10M | -342.69M | 484.98M | -1.18B |
Trans Genic Inc. Technical Analysis
Negative
254.00
Price Trends
252.96
Negative
271.76
Negative
256.97
Negative
Market Momentum
-12.78
Positive
35.75
Neutral
28.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Negative. The current price of 254 is above the 20-day moving average (MA) of 234.00, above the 50-day MA of 252.96, and below the 200-day MA of 256.97, indicating a bearish trend. The MACD of -12.78 indicates Positive momentum. The RSI at 35.75 is Neutral, neither overbought nor oversold. The STOCH value of 28.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2342.
Trans Genic Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | ¥1.49B | 12.03 | ― | ― | 1.57% | ― | |
58 Neutral | ¥5.91B | 87.86 | ― | 1.24% | -7.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.96B | -34.88 | ― | ― | -11.11% | -187.80% | |
43 Neutral | ¥3.61B | -46.12 | ― | ― | 1.30% | 92.91% | |
42 Neutral | ¥12.35B | -20.82 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.42B | -8.41 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:2342
Trans Genic Inc.
214.00
34.00
18.89%
JP:4880
CellSource Co., Ltd.
303.00
-390.04
-56.28%
JP:4978
ReproCELL Inc.
130.00
-57.00
-30.48%
JP:6190
PhoenixBio Co., Ltd.
370.00
-25.00
-6.33%
JP:7774
Japan Tissue Engineering Co., Ltd.
623.00
3.00
0.48%
JP:7776
CellSeed Inc.
219.00
-294.00
-57.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.